Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Watch CNN on your browser Desktop and Mobile Web. Tap Live TV on the main navigation.